RxDoctor Payments Data

Ellen Hoffer, NP

Family · Warwick, RINPI 1760639280

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 76.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,182 and has fallen 91.2% since, to $192 in 2025. Among family clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,101in general payments, 2019–2025

Across 48 payments — averaging $64.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Johnson & Johnson$146
  • E.r. Squibb & Sons, L.L.C.$144
  • Bridgebio Pharma, Inc.$119
  • AstraZeneca$117
  • Kiniksa Pharmaceuticals International, PLC$62
  • plus $131 from 3 others

What the payments were for

  • Travel & lodging$1,47147%
  • Food & beverage$1,56851%
  • Education$632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,101 in reported general payments places this provider in the 90th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$15,407
Medicare patients
144
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$23,323
XareltoRivaroxaban15$10,794
Metoprolol Succinate118$1,289
Flecainide Acetate20$921
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$595
Amiodarone Hcl24$549
Bumetanide14$497
Rosuvastatin Calcium11$255
Cephalexin38$195
Losartan Potassium22$164
Metoprolol Tartrate21$87
Furosemide14$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$146$10,79415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 457 family providers in Rhode Island.

Other family in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →